Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

Benzinga · 08/30 16:07
Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.